Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy.

Francisco IdalsoagaCamila RoblesAndrea OrtizOscar CorsiEduardo Fuentes-LópezLuis Antonio DíazGustavo AyaresMarco ArreseJuan Pablo Arab

Published in: Therapeutic advances in gastroenterology (2024)

The use of rifaximin significantly reduces infections in patients with cirrhosis and HE. Despite rifaximin was associated with a decreased all-cause mortality, this impact was not statistically significant in the adjusted analysis.

Keyphrases

irritable bowel syndrome
heart failure
cardiovascular events
early onset
risk factors
type diabetes
atrial fibrillation
liver failure